AACC has announced that it is changing its name to the Association for Diagnostics & Laboratory Medicine (ADLM).

Co-Diagnostics announced on Tuesday that it has been awarded two grants from the Bill and Melinda Gates Foundation totaling $2.3 million for its tuberculosis and human papillomavirus tests.

Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset for patients with NSCLC to facilitate future novel research related to precision medicine, diagnostic development, and biomarker discovery.

Diagnostics company Novacyt UK has agreed to purchase UK-based genomic medicine company Yourgene Health in a £16.7m ($21.3m) deal.

Researchers have used laboratory-on-a-chip technology to create a low cost, sensitive tuberculosis (TB) test that could improve disease detection in high-endemic, under-resourced areas.

The US Food and Drug Administration (FDA) has granted approval for Lumos Diagnostics’ FebriDx rapid point-of-care (POC) test.

PamGene International said Tuesday that the European Innovation Council's Accelerator program will provide €7.5 million ($8.2 million) in funding to develop and market the firm's prognostic test for immunotherapy response in metastatic cancer treatment.

Quest Diagnostics said it completed its previously announced acquisition of Haystack Oncology.

Paige is enhancing its suite of AI-enabled solutions designed to support pathologists in the diagnosis of breast cancer while decreasing subjectivity and the tedium of manual analysis.

On March 30 2023, Kalorama Information indicates that the global IVD market is now over $124 billion, with operations in more than 20 key healthcare and medical areas, such as infectious disease immunoassays, POC, molecular microbiology, clinical chemistry, etc.